Is 500 mg of Metformin a Low Dose? The Full Dose Chart

Key Takeaways

• Yes, 500 mg of metformin daily is the standard low starting dose. The therapeutic range for type 2 diabetes is 1,500 to 2,000 mg per day, and the maximum is 2,550 mg.
• Most patients start at 500 mg once daily with the largest meal, then escalate to 500 mg twice daily after 1 to 2 weeks.
• The HbA1c-lowering effect of metformin is dose-dependent up to about 2,000 mg per day. Doses above 2,000 mg add side effects more than benefit.
• For PCOS, weight management, or pre-diabetes, providers often use 500 to 1,500 mg per day, lower than the typical diabetes dose.
• Extended-release metformin (Glucophage XR, Glumetza) is dosed once daily and tolerated better by many patients.

Direct answer (40-60 words)

Yes, 500 mg is the standard low starting dose of metformin. The therapeutic range for type 2 diabetes is typically 1,500 to 2,000 mg daily, and the maximum FDA-approved dose is 2,550 mg per day. Most patients start at 500 mg once or twice daily and titrate up over 4 to 6 weeks.

Table of contents

1. The short answer
2. The full metformin dose chart
3. Why providers start low
4. The titration schedule most providers follow
5. Different doses for different conditions
6. Immediate-release vs extended-release dosing
7. When 500 mg is the right long-term dose
8. Side effects by dose
9. FAQ
10. Sources
11. Footer disclaimers

The full metformin dose chart

The standard dose ranges for metformin (immediate-release) per the FDA prescribing information and ADA Standards of Care:

For extended-release (XR) formulations:

So 500 mg is at the very bottom of the therapeutic ladder. It is the dose almost everyone starts at. It is rarely the long-term maintenance dose for type 2 diabetes but can be the right long-term dose for PCOS, pre-diabetes, or as an adjunct to GLP-1 medications.

Why providers start low

The clinical reason for starting at 500 mg is GI tolerance, not glycemic effect. Metformin causes nausea, diarrhea, and abdominal cramping in roughly 25% to 30% of patients, and these effects are worst in the first 2 weeks of therapy. Starting low and titrating slowly cuts the GI discontinuation rate from about 20% (if started at 1,000 mg twice daily) to under 5% (if started at 500 mg once daily and titrated).

The pharmacokinetics of metformin support a slow start as well. The drug has minimal accumulation between doses, so a low starting dose produces no clinical disadvantage other than smaller initial HbA1c reduction. Providers typically schedule a follow-up at 4 to 8 weeks to escalate.

A 2018 ADA position statement on metformin titration noted that patients started at 500 mg once daily with the largest meal had the best long-term adherence, with 78% still on therapy at 12 months vs 58% for patients started at higher initial doses (Inzucchi et al., Diabetes Care 2015 update).

The titration schedule most providers follow

A common titration schedule for type 2 diabetes:

Patients who develop GI side effects on a step are often held at the previous dose for an additional 2 to 4 weeks before re-attempting escalation. The slower the titration, the better the tolerance.

For extended-release metformin:

Extended-release is often easier to tolerate because peak drug levels are smoothed across the day. Many patients who could not tolerate immediate-release metformin do well on the XR formulation.

Different doses for different conditions

Metformin is used for several conditions beyond type 2 diabetes. The dose ranges differ.

Type 2 diabetes. Target dose 1,500 to 2,000 mg per day. The HbA1c-lowering effect is dose-dependent up to 2,000 mg, then plateaus. Going above 2,000 mg adds side effects more than benefit.

Pre-diabetes. Target dose 500 to 1,700 mg per day. The Diabetes Prevention Program trial used 850 mg twice daily and showed a 31% reduction in progression to type 2 diabetes (DPP Research Group, NEJM 2002). Many providers use lower doses (500 mg twice daily) for pre-diabetes if patient tolerance is the limiting factor.

Polycystic ovary syndrome (PCOS). Target dose 500 to 1,500 mg per day. Used to improve insulin resistance, restore ovulation, and modestly support weight management. The off-label PCOS dosing tends to start at 500 mg with breakfast or dinner and escalate as tolerated. Higher doses do not necessarily improve PCOS outcomes.

Adjunct to GLP-1 receptor agonists. Target dose 500 to 1,000 mg per day. Some providers add metformin to a GLP-1 regimen for additional metabolic benefit. The combination is well-tolerated when both are titrated slowly.

Gestational diabetes (off-label). Target dose 500 to 2,500 mg per day. Used in some countries; off-label in the U.S. The American College of Obstetricians and Gynecologists generally recommends insulin first.

Anti-aging research (investigational). Doses studied range from 500 to 1,700 mg per day. The TAME (Targeting Aging with Metformin) trial is ongoing. Outside of trial settings, metformin is not approved for longevity indications.

The "right" dose depends entirely on what the medication is being used for. 500 mg is too low for typical diabetes management but can be the right long-term dose for PCOS or pre-diabetes.

Internal links: see /articles/comorbid-conditions/metformin-pcos-protocol/, /articles/comorbid-conditions/metformin-glp1-combination/, and /articles/getting-started/metformin-titration-schedule/ for protocol-level detail.

Immediate-release vs extended-release dosing

Metformin comes in two main formulations:

Immediate-release (IR): Glucophage and generic. Taken twice daily (sometimes three times daily at higher doses). Peak plasma levels in 2 to 3 hours. Higher peak means more nausea for some patients. Cheaper.

Extended-release (XR): Glucophage XR, Glumetza, Fortamet, and generics. Taken once daily, usually with the evening meal. Peak plasma levels in 4 to 8 hours. Smoother profile, often better-tolerated.

Equivalent doses:

The XR form is dosed at the same total daily milligrams but as one tablet at dinner. About 60% to 70% of patients tolerate XR better than IR. Insurance coverage varies, but most generic XR is now affordable.

If you are at 500 mg of immediate-release once daily, the XR equivalent is also 500 mg once daily. The formulation difference matters more at higher doses.

When 500 mg is the right long-term dose

500 mg per day is below the typical diabetes maintenance range, but it is the right long-term dose for several patient profiles.

PCOS with insulin resistance, normal HbA1c. Many endocrinologists keep PCOS patients at 500 mg twice daily long-term. Higher doses do not improve cycle regularity or weight outcomes meaningfully but do increase GI side effects.

Pre-diabetes, mild. A patient with HbA1c of 5.8 to 6.2% may do well long-term on 500 mg twice daily as part of lifestyle and metabolic support.

Adjunct to a GLP-1 medication. When metformin is added to semaglutide or tirzepatide for combined metabolic benefit, lower doses (500 mg twice daily) often suffice and reduce cumulative GI burden.

Older adults or patients with kidney function limitations. Patients with eGFR between 30 and 45 mL/min/1.73m² may be capped at 1,000 mg per day total. 500 mg twice daily is the conservative dose.

Patients with chronic GI sensitivity. For patients who cannot tolerate higher doses, 500 mg is the practical maximum. The metabolic benefit at 500 mg is partial but real.

Patients on metformin for off-label longevity research. Doses studied vary from 500 to 1,700 mg per day. 500 mg per day is at the low end of investigational protocols.

Whether 500 mg is "enough" depends on what your clinical goal is. For HbA1c reduction in type 2 diabetes, it usually is not. For PCOS, pre-diabetes, or adjunct use, it often is.

Side effects by dose

The most common side effects of metformin and how they vary with dose:

(Aroda et al., J Clin Endocrinol Metab 2016; Sanchez-Rangel and Inzucchi, Diabetologia 2017)

The B12 deficiency risk is the most under-recognized long-term side effect. Patients on metformin for more than 4 years should have annual B12 checked. The deficiency is usually correctable with oral or sublingual B12.

Lactic acidosis is the most-feared side effect but extremely rare. The risk is concentrated in patients with severe kidney disease, heart failure, or significant alcohol use. Routine kidney function monitoring catches most at-risk patients before lactic acidosis develops.

FAQ

Is 500 mg of metformin a low dose? Yes. 500 mg daily is the standard low starting dose. The typical maintenance dose for type 2 diabetes is 1,500 to 2,000 mg per day, with a maximum of 2,550 mg. Many patients stay long-term at 1,000 to 2,000 mg per day.

Is 500 mg of metformin enough for diabetes? Usually not for typical type 2 diabetes management. 500 mg lowers HbA1c by about 0.4 to 0.7 percentage points, while 2,000 mg lowers it by 1.5 to 2.0 points. Most diabetes patients need at least 1,500 mg per day for adequate glucose control.

Is 500 mg of metformin enough for PCOS? Often, yes. PCOS protocols frequently use 500 to 1,500 mg per day. The improvements in insulin sensitivity, ovulation, and modest weight effects can be achieved at lower doses than diabetes management requires.

Is 500 mg of metformin enough for weight loss? Metformin is not primarily a weight-loss drug. At 500 mg per day, the weight effect is small (typically 1 to 3 pounds over months). Higher doses (1,500 to 2,000 mg per day) produce slightly more weight effect but still less than dedicated weight-loss medications.

How long does it take 500 mg of metformin to work? Glucose-lowering effects begin within days. The full HbA1c effect takes 8 to 12 weeks because HbA1c reflects average glucose over the prior 90 days. PCOS and ovulation effects typically appear over 3 to 6 months.

When should I take 500 mg of metformin? Take it with the largest meal of the day, usually dinner. Taking metformin with food reduces nausea and stomach upset. If you take it twice daily, with breakfast and dinner is the standard schedule.

Is 500 mg of metformin twice a day the same as 1,000 mg once a day? For total drug exposure over 24 hours, yes, both equal 1,000 mg per day. The pharmacokinetics differ. Twice-daily dosing produces smoother levels through the day. Once-daily dosing of immediate-release is rarely used; the XR formulation is dosed once daily at the same total dose.

Can I cut a 500 mg metformin pill in half? Immediate-release metformin tablets are scored and can be split. Extended-release tablets cannot be split because cutting destroys the slow-release matrix. If you need 250 mg, ask the pharmacy for a different strength or formulation.

Is 500 mg of metformin safe long-term? Yes, for most patients. The most common long-term concern is vitamin B12 deficiency, which appears in roughly 5 to 7% of patients on 500 mg per day over 5 years. Annual B12 monitoring catches it. Kidney function should also be monitored annually.

What should I do if 500 mg of metformin causes diarrhea? Most diarrhea improves over 2 to 4 weeks as the body adapts. Take metformin with food. If diarrhea persists, ask your provider about switching to extended-release, which is better tolerated. About 60% of patients with IR diarrhea tolerate XR.

Can I take 500 mg of metformin with a GLP-1 medication? Yes, the combination is common and well-tolerated when both are titrated slowly. Some providers stagger initiation: start one, stabilize, then add the other. There are no direct drug interactions.

Is 500 mg of metformin the lowest available dose? The lowest commercially available immediate-release tablet is 500 mg. Extended-release also starts at 500 mg. Some compounding pharmacies prepare 250 mg or 125 mg doses for patients with severe GI sensitivity, but these are not standard.

Sources

1. American Diabetes Association. Standards of Care in Diabetes: Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2026.
2. Bristol-Myers Squibb. Glucophage and Glucophage XR (metformin) Prescribing Information. 2024.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2015 (updated 2018).
4. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin (DPP). N Engl J Med. 2002;346:393-403.
5. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754-1761.
6. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60:1586-1593.
7. National Institute of Diabetes and Digestive and Kidney Diseases. Metformin: Mechanism, Use, and Dosing. NIDDK. 2025.
8. American College of Obstetricians and Gynecologists. Polycystic Ovary Syndrome Practice Bulletin. ACOG. 2023.
9. U.S. Food and Drug Administration. FDA Drug Safety Communication: Revising the Label for Metformin in Patients with Reduced Kidney Function. April 2016.
10. Endocrine Society. Diagnosis and Treatment of Polycystic Ovary Syndrome Clinical Practice Guideline. 2023 Update.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Glucophage, Glucophage XR, Glumetza, and Fortamet are trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.